CellCentric advances blood cancer trial
Anchored locally at Chesterford Research Park, the clinical-stage enterprise is developing inobrodib, a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma (MM).
The current trials are evaluating inobrodib in combination with B-cell maturation antigen (BCMA) directed CD3 T-cell engagers.
Some 40 patients are expected to receive the combination of inobrodib with one of two bispecific agents. Initial safety evaluation data is expected by the end of 2025. Other treatment regimens are also being assessed as part of this study.
CellCentric CEO Will West said: “We’re excited to build upon the positive data presented at ASH 2024, which demonstrated encouraging clinical activity for inobrodib both as a monotherapy and in combination.
“Based on these results, we are rapidly advancing inobrodib across several treatment settings in multiple myeloma. As a first-in-class agent with a favourable safety profile, we believe inobrodib has broad therapeutic potential, including in combination with a range of other therapies such as bispecific antibodies that have transformed the multiple myeloma treatment landscape in recent years.”
In recent months, CellCentric says it has generated significant momentum. In April, the company opened a new office in the Boston area, expanding both its US footprint and development capacity.
A month later it secured a $120 million Series C funding round, co-led by RA Capital Management and Forbion, to accelerate registration trials for inobrodib and evaluate bispecific antibody combinations. This progress has been complemented by expansion across all levels of the team, spanning clinical operations, regulatory and corporate functions.
Inobrodib is a first-in-class potential new treatment for people with cancer and multiple myeloma in particular. It is a small molecule drug that targets p300/CBP, lowering the expression of key cancer drivers, including MYC and IRF4.
It has been evaluated in over 400 patients to date and has a favourable safety and tolerability profile. Clinical activity has been seen in multiple settings, both solid tumour and haematologic malignancies. Delivered as an oral capsule, it is easy for patients to take and can be used at home without the need for intensive monitoring.
Its differentiated profile may broaden use among patients who cannot tolerate or access other treatments, while its ease of administration could reduce healthcare system burden relative to more complex therapies.
CellCentric maintains development and commercial rights to inobrodib and is free to expand the programme in combination with other agents.
Privately owned CellCentric is backed by a global syndicate of life science investors including RA Captial Management, Forbion (ForCal), Morningside, Pfizer Ventures, Avego and the American Cancer Society’s BrightEdge Fund.